Skeletal muscle is 40% of body weight in a healthy adult and consumes roughly 80% of post-meal glucose.

Mounjaro and Zepbound are the same drug (tirzepatide) at the same dosing. There is no chemical withdrawal syndrome from either.

Mounjaro is tirzepatide approved for type 2 diabetes, dosed once weekly. The same molecule is sold as Zepbound for weight management.

The Mounjaro shortage was declared resolved by the FDA in December 2024, alongside Zepbound, which shares the same tirzepatide molecule.

The first week on Mounjaro is mostly an adaptation week, not a weight loss week.

Six months on Mounjaro is where the dual GIP/GLP-1 mechanism really separates from pure GLP-1 therapies.

Three months on Mounjaro lands most patients at 9 to 12 percent body weight loss and 2 to 3 dose escalations into the protocol.

Month 2 on Mounjaro is when most patients stop questioning whether the medication is working.

A year on Mounjaro is the data point that reshaped the GLP-1 landscape. SURMOUNT-1 (Jastreboff et al.